<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic treatment of recurrent meningioma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic treatment of recurrent meningioma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic treatment of recurrent meningioma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen A Shih, MD, MS, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H444763133"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Meningiomas account for approximately one-third of primary central nervous system tumors  (<a class="graphic graphic_table graphicRef81566" href="/z/d/graphic/81566.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef72275" href="/z/d/graphic/72275.html" rel="external">figure 1</a>). Surgery and/or radiation therapy (RT) constitutes the initial therapeutic approach. Furthermore, surgery and/or RT are able to control disease in some patients with recurrence.</p><p>Despite the appropriate use of surgery and RT for initial management and management of recurrent disease, there is a subset of patients in whom disease cannot be controlled with these approaches. Experience with systemic therapy is limited, and most data are from observational studies. Although a number of agents have been studied, none have an established role in prolonging progression-free or overall survival [<a href="#rid1">1</a>].</p><p>The available data for systemic therapy are reviewed here. Topics dealing with other aspects of meningioma management include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">"Epidemiology, pathology, clinical features, and diagnosis of meningioma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15692.html" rel="external">"Management of atypical and malignant (WHO grade 2 and 3) meningioma"</a>.)</p><p></p><p class="headingAnchor" id="H444763147"><span class="h1">HORMONAL THERAPY</span><span class="headingEndMark"> — </span>Epidemiologic evidence suggests that there is a link between hormonal factors and the development or progression of meningiomas. Progesterone and androgen receptors are expressed on approximately two-thirds of meningiomas and estrogen receptor is expressed on approximately 10 percent [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">"Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Hormonal factors'</a>.)</p><p>Inhibition of these receptors has not been demonstrated to alter the natural history of recurrent meningiomas:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progesterone receptor inhibition</strong> – Small studies with the progesterone receptor inhibitor <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> suggested that this agent resulted in objective improvement in 25 to 30 percent of patients with unresectable meningioma [<a href="#rid3">3-5</a>]. However, a multicenter cooperative group phase III trial failed to demonstrate any benefit from treatment with mifepristone [<a href="#rid6">6</a>]. In this trial, 180 patients were randomly assigned to either mifepristone or placebo. There was no improvement in median progression-free survival (PFS; 10 versus 12 months). The lack of activity in this trial may have been due to loss of expression of progesterone receptor in patients with advanced disease [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen receptor inhibitors</strong> – Two studies have evaluated <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> in patients with inoperable meningiomas, without definitive evidence of clinical activity [<a href="#rid7">7,8</a>]. In the larger of these, a Southwest Oncology Group study, 21 patients were treated; only one partial response was observed [<a href="#rid7">7</a>]. The poor response rate may reflect the low rate of expression of estrogen receptor in patients with meningioma [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgen receptor inhibitors</strong> – No formal clinical studies have been reported with antiandrogens. Experience with a limited number of patients has not demonstrated useful clinical activity [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H444763154"><span class="h1">CHEMOTHERAPY</span><span class="headingEndMark"> — </span>A variety of chemotherapy agents has been studied in small series, including <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid9">9</a>], <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> [<a href="#rid10">10</a>], and combinations such as <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid11">11</a>]. Results with these approaches have not provided evidence of significant activity [<a href="#rid2">2</a>].</p><p>The most extensively studied agent is <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. Early studies reported imaging evidence of tumor shrinkage or seemingly prolonged stable disease [<a href="#rid2">2</a>]. However, these observations were not confirmed in a phase II study conducted by the Southwest Oncology Group (S9811) [<a href="#rid9">9</a>]. There were no objective responses in the 29 patients with measurable, biopsy-proven benign meningiomas, although the median progression-free survival (PFS) was 27 months and the three-year PFS rate was 43 percent. Whether this represents an effect on the natural history of benign meningiomas is unclear.</p><p><a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">Trabectedin</a>, an antineoplastic drug with activity in some forms of sarcoma, did not improve progression-free or overall survival compared with local standard of care in a multicenter phase II randomized trial in Europe [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H444763168"><span class="h1">SOMATOSTATIN ANALOGS</span><span class="headingEndMark"> — </span>Somatostatin receptors are expressed in approximately 90 percent of meningiomas [<a href="#rid2">2</a>]. Although case reports initially suggested that therapy targeted to this pathway might have therapeutic usefulness for patients with recurrent, unresectable meningiomas [<a href="#rid13">13-15</a>], subsequent trials have not shown clear benefit.</p><p>A prospective pilot study treated 16 patients with a long-acting formulation of the somatostatin analog <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid16">16</a>]. All patients had recurrent, progressive meningioma and at least six months had passed since prior radiation therapy (RT). All of the meningiomas expressed somatostatin receptors as demonstrated by a radiolabeled octreotide scan. Partial responses were observed in five patients (31 percent) and another five patients had stable disease. The median survival was eight months.</p><p>A subsequent prospective, two-stage phase II trial of <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> in patients with recurrent high-grade meningioma was stopped early due to lack of efficacy, after only nine patients were enrolled [<a href="#rid17">17</a>].</p><p>Another somatostatin analog, <a class="drug drug_general" data-topicid="87457" href="/z/d/drug information/87457.html" rel="external">pasireotide</a> (SOM230C), was evaluated in a multicenter, phase II trial in patients with recurrent, progressive meningioma [<a href="#rid18">18</a>]. There did not appear to be significant activity. No responses were observed; progression-free survival (PFS) at six months was 15 percent for grade 2 and 3 meningiomas and 50 percent for grade 1 tumors.</p><p class="headingAnchor" id="H444763175"><span class="h1">MOLECULARLY TARGETED AGENTS</span><span class="headingEndMark"> — </span>An increasing understanding of the cell signaling pathways has led to the identification of other pathways and potential targets for therapeutic intervention [<a href="#rid2">2</a>]. Several of these approaches are being evaluated in meningioma patients requiring systemic therapy. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet-derived growth factor</strong> – Platelet-derived growth factor (PDGF) stimulates tumor cell growth in a number of tumors. PDGF receptors are commonly expressed on the cell surface of meningiomas. <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">Imatinib</a>, an inhibitor of the PDGF receptors, has been evaluated in phase II studies either alone [<a href="#rid19">19</a>] or in combination with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid20">20</a>]. No objective responses or prolongation in progression-free survival (PFS) were identified by imaging in either study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidermal growth factor</strong> – Epidermal growth factor receptor (EGFR) is overexpressed on more than 60 percent of meningiomas [<a href="#rid2">2</a>]. The EGFR tyrosine kinase inhibitors <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> and <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> were evaluated in two multicenter studies [<a href="#rid21">21</a>]. No objective responses were observed and the studies concluded that these agents did not have clinically useful activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiogenesis inhibition</strong> – Meningiomas are vascular tumors, suggesting that inhibition of angiogenesis might be a clinically useful approach [<a href="#rid2">2</a>]. <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a>, a monoclonal antibody that binds vascular endothelial growth factor (VEGF), has been associated with disease stabilization in case reports of patients with recurrent and refractory meningiomas [<a href="#rid22">22,23</a>]. In a phase II multicenter trial of bevacizumab monotherapy that included 42 patients with progressive meningioma of any grade and eight other nonparenchymal tumors, the majority of patients achieved stable disease as a best response [<a href="#rid24">24</a>]. PFS at six months (PFS-6) was 93 percent for grade 1 meningiomas, 85 percent for grade 2 meningiomas, and 51 percent for grade 3 meningiomas. Median overall survival for grade 1, 2, and 3 meningiomas was 35, 27, and 12 months, respectively. These outcomes reflect an improvement compared with a historical PFS-6 benchmark of approximately 25 percent for recurrent/refractory meningiomas [<a href="#rid25">25</a>], although confidence is limited by disease heterogeneity and lack of prospective randomized trials. Nonetheless, bevacizumab was well tolerated in the phase II trial, with expected rates of hypertension and proteinuria and no treatment-related deaths [<a href="#rid24">24</a>]. The anti-edema effects of bevacizumab may help to reduce steroid toxicities in patients with symptomatic edema, although this has also not been well studied prospectively.</p><p></p><p class="bulletIndent1">In a multicenter, phase II trial of <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> in 36 heavily pretreated patients with high-grade meningioma (30 atypical and 6 anaplastic), PFS at six months was 42 percent, meeting the primary endpoint [<a href="#rid26">26</a>]. Median PFS was five months, and median overall survival was 25 months. Overall toxicity included one grade 5 intratumoral hemorrhage, two grade 3 and one grade 4 intracranial/intratumoral hemorrhages, one grade 3 and one grade 4 thrombotic microangiopathy, and one grade 3 gastrointestinal perforation. PFS was longer in patients whose tumors expressed vascular endothelial growth factor receptor 2 (VEGFR2; median PFS 6.4 versus 1.4 months, p = 0.005). This study, along with case reports, suggests that sunitinib may have activity in recurrent grade 2 and 3 meningiomas, although it is not very well tolerated and predictors of response are not yet well understood [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1">Other agents being investigated to target angiogenesis include vatalanib [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pi3K/Akt/mTOR pathway</strong> – Most meningiomas show evidence of upregulation or overexpression of the Pi3K/Akt/mTOR pathway. Preclinical data indicate that inhibition of mechanistic target of rapamycin (mTOR) with agents such as <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> may be an effective strategy [<a href="#rid29">29,30</a>]. In a phase II study of <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> plus everolimus in 20 patients with recurrent/refractory meningiomas, the six-month PFS was 55 percent, and the majority of tumors (78 percent) experienced &gt;50 percent reduction in the rate of growth at three months [<a href="#rid31">31</a>]. Everolimus has also been combined with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in a small prospective trial that was stopped early due to slow accrual [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H478660303"><span class="h1">GENOTYPE-DIRECTED THERAPY</span><span class="headingEndMark"> — </span>Next-generation sequencing of meningiomas has revealed that approximately 8 percent of grade 1 meningiomas ha<em>ve AKT1</em> mutations, 5 percent have smoothened (<em>SMO</em>) mutations, and over 50 percent have NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor<em> </em>(<em>NF2</em>) mutations [<a href="#rid33">33,34</a>]<em>. AKT1</em> a<em>nd SMO</em> mutations are primarily identified in skull base meningiomas. Trials with agents targeting these mutations are ongoing [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">"Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Molecular pathogenesis'</a>.)</p><p class="headingAnchor" id="H4132102083"><span class="h1">IMMUNOTHERAPY</span><span class="headingEndMark"> — </span>As in many other cancer types, there is increasing interest in modulation of local immune responses in meningioma. At least one study has found evidence of increased programmed death ligand 1 (PD-L1) expression in archival anaplastic meningioma specimens [<a href="#rid36">36</a>], prompting trials of anti-programmed cell death 1 (PD-1) therapies in patients with refractory grade 2 and 3 tumors.</p><p>In a phase II trial of 25 patients with recurrent atypical or anaplastic meningioma, the PD-1 inhibitor <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> was associated with one radiographic response, which was ongoing at 4.5 years [<a href="#rid37">37</a>]. Six-month progression-free survival and overall survival were 42 percent and 31 months, respectively. No molecular or clinical predictors of response could be identified, although sample numbers were low and few tumors had evidence of high mutational burden.</p><p>Some meningiomas are found to have evidence of high mutational tumor burden, high-frequency microsatellite instability (MSI-H), and/or mismatch repair (MMR) deficiency on sequencing that may increase the likelihood of responsiveness to immunotherapy. In a study that included over 1000 meningioma samples, 2.5 percent of tumors had a high tumor mutational burden, including six samples (0.6 percent), all high-grade tumors, with detectable inactivating mutations in MMR-related genes [<a href="#rid38">38</a>]. One patient with an <em>MSH2</em>-deficient meningioma experienced a dramatic and durable response to <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>.</p><p>Although rare, such genetic changes are important to recognize in patients with recurrent/refractory meningioma for the purposes of clinical trial eligibility as well as approved therapies. As an example, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is approved for use in the United States for patients with MSI-H or MMR-deficient advanced solid tumors that have progressed following prior treatment and for which there are no satisfactory alternative treatment options. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p>Of note, patients with tumor-associated MSI-H or MMR deficiency have an increased risk of Lynch syndrome cancer predisposition and should be referred for genetic counseling and germline genetic assessment for Lynch syndrome, regardless of family history [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Microsatellite instability testing'</a>.)</p><p class="headingAnchor" id="H2285301027"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">"Society guideline links: Primary brain tumors"</a>.)</p><p class="headingAnchor" id="H444763182"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of systemic therapy</strong> – There is no established systemic therapy that has been shown to effectively treat recurrent meningioma or to increase survival. Whenever possible, such patients should be enrolled into formal clinical protocols.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Options for recurrent tumors</strong> – For patients who are not eligible for inclusion on a protocol and are not candidates for re-irradiation or further surgery, options include <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>, and a vascular endothelial growth factor receptor (VEGFR) inhibitor. Selection is individualized; for patients with symptomatic edema or steroid toxicities, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> may be favored based on its concurrent anti-edema effects. (See <a class="local">'Chemotherapy'</a> above and <a class="local">'Somatostatin analogs'</a> above and <a class="local">'Molecularly targeted agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapy</strong> – Some meningiomas are found to have evidence of high mutational tumor burden, high-frequency microsatellite instability (MSI-H), and/or mismatch repair (MMR) deficiency on sequencing that may increase the likelihood of responsiveness to immunotherapy. (See <a class="local">'Immunotherapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep 2009; 9:231.</a></li><li><a class="nounderline abstract_t">Wen PY, Quant E, Drappatz J, et al. Medical therapies for meningiomas. J Neurooncol 2010; 99:365.</a></li><li><a class="nounderline abstract_t">Koide SS. Mifepristone. Auxiliary therapeutic use in cancer and related disorders. J Reprod Med 1998; 43:551.</a></li><li><a class="nounderline abstract_t">Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74:861.</a></li><li><a class="nounderline abstract_t">Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006; 24:727.</a></li><li><a class="nounderline abstract_t">Grunberg SM, Rankin C, Townsend J. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clinical Oncol 2001; 20:56a.</a></li><li><a class="nounderline abstract_t">Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 1993; 15:75.</a></li><li><a class="nounderline abstract_t">Markwalder TM, Seiler RW, Zava DT. Antiestrogenic therapy of meningiomas--a pilot study. Surg Neurol 1985; 24:245.</a></li><li><a class="nounderline abstract_t">Swinnen LJ, Rankin C, Rushing EJ. Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma. J Clin Oncol 2009; 27:15s.</a></li><li><a class="nounderline abstract_t">Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004; 62:1210.</a></li><li><a class="nounderline abstract_t">Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996; 84:733.</a></li><li><a class="nounderline abstract_t">Preusser M, Silvani A, Le Rhun E, et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol 2022; 24:755.</a></li><li><a class="nounderline abstract_t">García-Luna PP, Relimpio F, Pumar A, et al. Clinical use of octreotide in unresectable meningiomas. A report of three cases. J Neurosurg Sci 1993; 37:237.</a></li><li><a class="nounderline abstract_t">Rünzi MW, Jaspers C, Windeck R, et al. Treatment of meningioma with octreotide. Lancet 1989; 2:217.</a></li><li><a class="nounderline abstract_t">Jaffrain-Rea ML, Minniti G, Santoro A, et al. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin Neurol Neurosurg 1998; 100:40.</a></li><li><a class="nounderline abstract_t">Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007; 69:969.</a></li><li><a class="nounderline abstract_t">Simó M, Argyriou AA, Macià M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol 2014; 73:919.</a></li><li><a class="nounderline abstract_t">Norden AD, Ligon KL, Hammond SN, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 2015; 84:280.</a></li><li><a class="nounderline abstract_t">Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 2009; 11:853.</a></li><li><a class="nounderline abstract_t">Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 2012; 106:409.</a></li><li><a class="nounderline abstract_t">Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 2010; 96:211.</a></li><li><a class="nounderline abstract_t">Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 2012; 109:63.</a></li><li><a class="nounderline abstract_t">Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012; 109:187.</a></li><li><a class="nounderline abstract_t">Kumthekar P, Grimm SA, Aleman RT, et al. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv 2022; 4:vdac123.</a></li><li><a class="nounderline abstract_t">Kaley T, Barani I, Chamberlain M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol 2014; 16:829.</a></li><li><a class="nounderline abstract_t">Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 2015; 17:116.</a></li><li><a class="nounderline abstract_t">Raheja A, Colman H, Palmer CA, Couldwell WT. Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report. J Neurosurg 2017; 127:965.</a></li><li><a class="nounderline abstract_t">Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol 2014; 117:93.</a></li><li><a class="nounderline abstract_t">Pachow D, Andrae N, Kliese N, et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res 2013; 19:1180.</a></li><li><a class="nounderline abstract_t">Graillon T, Defilles C, Mohamed A, et al. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. J Neurooncol 2015; 124:33.</a></li><li><a class="nounderline abstract_t">Graillon T, Sanson M, Campello C, et al. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clin Cancer Res 2020; 26:552.</a></li><li><a class="nounderline abstract_t">Shih KC, Chowdhary S, Rosenblatt P, et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 2016; 129:281.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013; 45:285.</a></li><li><a class="nounderline abstract_t">Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339:1077.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Twohy EL, Gerstner ER, et al. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. J Clin Oncol 2023; 41:618.</a></li><li><a class="nounderline abstract_t">Du Z, Abedalthagafi M, Aizer AA, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 2015; 6:4704.</a></li><li><a class="nounderline abstract_t">Bi WL, Nayak L, Meredith DM, et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol 2022; 24:101.</a></li><li><a class="nounderline abstract_t">Dunn IF, Du Z, Touat M, et al. Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol 2018; 2018.</a></li><li><a class="nounderline abstract_t">Latham A, Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 2019; 37:286.</a></li></ol></div><div id="topicVersionRevision">Topic 15693 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19348712" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Advances in meningioma therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20820875" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Medical therapies for meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9693404" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mifepristone. Auxiliary therapeutic use in cancer and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2033444" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162554" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8455065" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4023903" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antiestrogenic therapy of meningiomas--a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15079029" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Temozolomide for treatment-resistant recurrent meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622144" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adjuvant combined modality therapy for malignant meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34672349" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7931648" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical use of octreotide in unresectable meningiomas. A report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2568544" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of meningioma with octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637203" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Visual improvement during octreotide therapy in a case of episellar meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785665" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24619496" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527270" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293394" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21938530" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Phase II study of Gleevec®plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19562255" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22535433" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22544653" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Atypical and anaplastic meningiomas treated with bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36225651" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500419" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25100872" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27935362" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24449400" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406776" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : mTORC1 inhibitors suppress meningioma growth in mouse models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26015296" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31969329" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27311730" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334667" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348505" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36288512" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25609200" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34015129" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30801050" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30376427" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
